281 related articles for article (PubMed ID: 16419069)
1. Adjuvant chemotherapy in muscle-invasive bladder carcinoma: a pooled analysis from phase III studies.
Ruggeri EM; Giannarelli D; Bria E; Carlini P; Felici A; Nelli F; Gallucci M; Cognetti F; Pollera CF
Cancer; 2006 Feb; 106(4):783-8. PubMed ID: 16419069
[TBL] [Abstract][Full Text] [Related]
2. Adjuvant chemotherapy for deep muscle-invasive transitional cell bladder carcinoma - a practice guideline.
Segal R; Winquist E; Lukka H; Chin JL; Brundage M; Markman BR;
Can J Urol; 2002 Oct; 9(5):1625-33. PubMed ID: 12431323
[TBL] [Abstract][Full Text] [Related]
3. The effect of cystectomy, and perioperative methotrexate, vinblastine, doxorubicin and cisplatin chemotherapy on the risk and pattern of relapse in patients with muscle invasive bladder cancer.
Ennis RD; Petrylak DP; Singh P; Bagiella E; O'Toole KM; Benson MC; Olsson CA
J Urol; 2000 May; 163(5):1413-8. PubMed ID: 10751847
[TBL] [Abstract][Full Text] [Related]
4. Prognostic significance of adjuvant cisplatin-based combination chemotherapy following radical cystectomy in patients with invasive bladder cancer.
Muramaki M; Miyake H; Kurahashi T; Takenaka A; Inoue TA; Fujisawa M
Int J Urol; 2008 Apr; 15(4):314-8. PubMed ID: 18380818
[TBL] [Abstract][Full Text] [Related]
5. Conservative treatment of invasive bladder carcinoma by transurethral resection, protracted intravenous infusion chemotherapy, and hyperfractionated radiotherapy: long term results.
Danesi DT; Arcangeli G; Cruciani E; Altavista P; Mecozzi A; Saracino B; Orefici F
Cancer; 2004 Dec; 101(11):2540-8. PubMed ID: 15481058
[TBL] [Abstract][Full Text] [Related]
6. Magnitude of benefit of adjuvant chemotherapy for non-small cell lung cancer: meta-analysis of randomized clinical trials.
Bria E; Gralla RJ; Raftopoulos H; Cuppone F; Milella M; Sperduti I; Carlini P; Terzoli E; Cognetti F; Giannarelli D
Lung Cancer; 2009 Jan; 63(1):50-7. PubMed ID: 18565615
[TBL] [Abstract][Full Text] [Related]
7. Superficial (pT2a) and deep (pT2b) muscle invasion in pathological staging of bladder cancer following radical cystectomy.
Yu RJ; Stein JP; Cai J; Miranda G; Groshen S; Skinner DG
J Urol; 2006 Aug; 176(2):493-8; discussion 498-9. PubMed ID: 16813876
[TBL] [Abstract][Full Text] [Related]
8. Perioperative chemotherapy in muscle-invasive bladder cancer to enhance survival and/or as a strategy for bladder preservation.
Sternberg CN
Semin Oncol; 2007 Apr; 34(2):122-8. PubMed ID: 17382795
[TBL] [Abstract][Full Text] [Related]
9. Complete long-term survival data from a trial of adjuvant chemotherapy vs control after radical cystectomy for locally advanced bladder cancer.
Lehmann J; Franzaring L; Thüroff J; Wellek S; Stöckle M
BJU Int; 2006 Jan; 97(1):42-7. PubMed ID: 16336326
[TBL] [Abstract][Full Text] [Related]
10. Outcome of patients who refuse cystectomy after receiving neoadjuvant chemotherapy for muscle-invasive bladder cancer.
Herr HW
Eur Urol; 2008 Jul; 54(1):126-32. PubMed ID: 18248875
[TBL] [Abstract][Full Text] [Related]
11. Adjuvant chemotherapy for bladder cancer.
Sternberg CN; Calabró F
Expert Rev Anticancer Ther; 2005 Dec; 5(6):987-92. PubMed ID: 16336089
[TBL] [Abstract][Full Text] [Related]
12. Low incidence of perioperative chemotherapy for stage III bladder cancer 1998 to 2003: a report from the National Cancer Data Base.
David KA; Milowsky MI; Ritchey J; Carroll PR; Nanus DM
J Urol; 2007 Aug; 178(2):451-4. PubMed ID: 17561135
[TBL] [Abstract][Full Text] [Related]
13. Neoadjuvant chemotherapy in patients with invasive bladder cancer.
Vaughn DJ; Malkowicz SB
Urol Clin North Am; 2005 May; 32(2):231-7. PubMed ID: 15862620
[TBL] [Abstract][Full Text] [Related]
14. Small cell carcinoma of the urinary bladder. The Mayo Clinic experience.
Choong NW; Quevedo JF; Kaur JS
Cancer; 2005 Mar; 103(6):1172-8. PubMed ID: 15700264
[TBL] [Abstract][Full Text] [Related]
15. Neoadjuvant cisplatinum based combination chemotherapy in patients with invasive bladder cancer: a combined analysis of two Nordic studies.
Sherif A; Holmberg L; Rintala E; Mestad O; Nilsson J; Nilsson S; Malmström PU;
Eur Urol; 2004 Mar; 45(3):297-303. PubMed ID: 15036674
[TBL] [Abstract][Full Text] [Related]
16. Patterns of recurrence and outcomes following induction bacillus Calmette-Guerin for high risk Ta, T1 bladder cancer.
Lerner SP; Tangen CM; Sucharew H; Wood D; Crawford ED
J Urol; 2007 May; 177(5):1727-31. PubMed ID: 17437798
[TBL] [Abstract][Full Text] [Related]
17. Neoadjuvant and adjuvant chemotherapy in muscle-invasive bladder cancer.
Calabrò F; Sternberg CN
Eur Urol; 2009 Feb; 55(2):348-58. PubMed ID: 18977070
[TBL] [Abstract][Full Text] [Related]
18. Hydronephrosis is an independent predictor of poor clinical outcome in patients treated for muscle-invasive transitional cell carcinoma with radical cystectomy.
Canter D; Guzzo TJ; Resnick MJ; Brucker B; Vira M; Chen Z; Tomaszewski J; VanArsdalen K; Wein AJ; Malkowicz SB
Urology; 2008 Aug; 72(2):379-83. PubMed ID: 18514771
[TBL] [Abstract][Full Text] [Related]
19. Integration of neoadjuvant and adjuvant chemotherapy and cystectomy in the treatment of muscle-invasive bladder cancer.
Milowsky MI; Stadler WM; Bajorin DF
BJU Int; 2008 Nov; 102(9 Pt B):1339-44. PubMed ID: 19035902
[TBL] [Abstract][Full Text] [Related]
20. Outcomes of radical cystectomy for transitional cell carcinoma of the bladder: a contemporary series from the Bladder Cancer Research Consortium.
Shariat SF; Karakiewicz PI; Palapattu GS; Lotan Y; Rogers CG; Amiel GE; Vazina A; Gupta A; Bastian PJ; Sagalowsky AI; Schoenberg MP; Lerner SP
J Urol; 2006 Dec; 176(6 Pt 1):2414-22; discussion 2422. PubMed ID: 17085118
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]